Kiromic Biopharma, Inc.: Nasdaq/NYSE listing notice — Kiromic BioPharma receives Nasdaq delisting notice; stock moves to OTC Pink

Kiromic Biopharma, Inc.

Received formal notice on Sept 12, 2023 for failure to comply with Nasdaq Listing Rule 5550(b)(1).
Trading on Nasdaq Capital Market suspended effective Sept 14, 2023.
Common stock will trade on OTC Pink Sheets under ticker KRBP starting Sept 14.
Company will pursue uplisting to OTCQB but no assurance of market development.
Delisting not expected to impact day-to-day operations, per company statement.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Kiromic Biopharma, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

September 12, 2023, Kiromic Biopharma, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that it would delist the Company’s shares of common stock from the Nasdaq Capital Market upon the opening of trading on September 14, 2023. The Company’s common stock will be traded on the OTC Pink Sheets while it pursues an uplisting to the OTCQB exchange and seeks to establish relationships with market makers to provide additional trading opportunities in the Company’s stock. However, there can be no assurance that a market for the Company’s shares w

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-015711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.